Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | TOP1 | P11387 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 3/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5749627 | 0.91 | TOP1 (0.62) | HRASESR1TOP1ESR2POLB | |
| SCHEMBL5745871 | 0.91 | TOP1 (0.62) | HRASESR1TOP1ESR2POLB | |
| SCHEMBL4850168 | 0.84 | HRAS (0.49) | HRASESR1TOP1ESR2POLB | |
| SCHEMBL14002833 | 0.83 | TOP1 (0.54) | HRASESR1TOP1ESR2POLB | |
| SCHEMBL5778912 | 0.81 | HRAS (0.40) | HRASESR1TOP1ESR2POLB | |
| SCHEMBL14441973 | 0.79 | CYP2C9 (0.43) | HRASESR1TOP1ESR2POLB | |
| SCHEMBL8889890 | 0.78 | TDP1 (0.41) | HRASESR1TOP1ESR2POLB | |
| SCHEMBL5748174 | 0.78 | TOP1 (0.62) | HRASESR1TOP1ESR2POLB | |
| SCHEMBL14002822 | 0.78 | TOP1 (0.62) | HRASESR1TOP1ESR2POLB | |
| SCHEMBL5746633 | 0.77 | HRAS (0.65) | HRASESR1TOP1ESR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060067997-A1 | Phospholipid complexes of lexitropsins, their preparation and use in therapeutic formulations | ARCAMONE FEDERICO | 2006-03-30 | — | — | US | claimed |
| EP-1536771-A1 | PHOSPHOLIPID COMPLEXES OF LEXITROPSINS, THEIR PREPARATION AND USE IN THERAPEUTIC FORMULATIONS | Arcamone, Federico (IT) | 2005-06-08 | — | — | EP | claimed |
| WO-2004004691-A1 | PHOSPHOLIPID COMPLEXES OF LEXITROPSINS, THEIR PREPARATION AND USE IN THERAPEUTIC FORMULATIONS | ARCAMONE FEDERICO (IT) | 2004-01-15 | — | — | WO | claimed |
| US-7449547-B2 | Process for the synthesis of distamycin and derivatives thereof using 1-methyl-4-formylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate | NAXOPHARMA S.R.L. (IT) | 2008-11-11 | — | — | US | disclosed |
| US-7449547-B2 | Process for the synthesis of distamycin and derivatives thereof using 1-methyl-4-formylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate | NAXOPHARMA S.R.L. (IT) | 2008-11-11 | — | — | US | disclosed |
| US-7449547-B2 | Process for the synthesis of distamycin and derivatives thereof using 1-methyl-4-formylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate | NAXOPHARMA S.R.L. (IT) | 2008-11-11 | — | — | US | disclosed |
| US-20070060523-A1 | Process for the synthesis of distamycin and derivatives thereof using 1-methyl-4-formylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate | NAXOSPHARMA S.R.L. (IT) | 2007-03-15 | — | — | US | disclosed |
| US-20070060523-A1 | Process for the synthesis of distamycin and derivatives thereof using 1-methyl-4-formylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate | NAXOSPHARMA S.R.L. (IT) | 2007-03-15 | — | — | US | disclosed |
| US-20070060523-A1 | Process for the synthesis of distamycin and derivatives thereof using 1-methyl-4-formylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate | NAXOSPHARMA S.R.L. (IT) | 2007-03-15 | — | — | US | disclosed |
| EP-1641753-B1 | PROCESS FOR THE SYNTHESIS OF DISTAMYCIN AND DERIVATIVES THEREOF USING 1-METHYL-4-FORMYLAMINO-2-PYRROLECARBONYL CHLORIDE ITERATIVELY AS AN INTERMEDIATE | NAXOSPHARMA S R L (IT) | 2006-10-18 | — | — | EP | disclosed |
| EP-1641753-A1 | PROCESS FOR THE SYNTHESIS OF DISTAMYCIN AND DERIVATIVES THEREOF USING 1-METHYL-4-FORMYLAMINO-2-PYRROLECARBONYL CHLORIDE ITERATIVELY AS AN INTERMEDIATE | Naxospharma S.R.L. (IT) | 2006-04-05 | — | — | EP | disclosed |
| US-20060067997-A1 | Phospholipid complexes of lexitropsins, their preparation and use in therapeutic formulations | ARCAMONE FEDERICO | 2006-03-30 | — | — | US | disclosed |
| EP-1536771-A1 | PHOSPHOLIPID COMPLEXES OF LEXITROPSINS, THEIR PREPARATION AND USE IN THERAPEUTIC FORMULATIONS | Arcamone, Federico (IT) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004106301-A1 | PROCESS FOR THE SYNTHESIS OF DISTAMYCIN AND DERIVATIVES THEREOF USING 1-METHYL-4-FORMYLAMINO-2-PYRROLECARBONYL CHLORIDE ITERATIVELY AS AN INTERMEDIATE | NAXOSPHARMA S.R.L. (IT) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004004691-A1 | PHOSPHOLIPID COMPLEXES OF LEXITROPSINS, THEIR PREPARATION AND USE IN THERAPEUTIC FORMULATIONS | ARCAMONE FEDERICO (IT) | 2004-01-15 | — | — | WO | disclosed |
| EP-0885189-A2 | METHOD FOR THE SYNTHESIS OF POLY-PYRROLE AND POLY-IMIDAZOLE CARBOXAMIDES ON A SOLID SUPPORT | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997030975-A2 | METHOD FOR THE SYNTHESIS OF POLY-PYRROLE AND POLY-IMIDAZOLE CARBOXAMIDES ON A SOLID SUPPORT | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060523-A1 | Process for the synthesis of distamycin and derivatives thereof using 1-methyl-4-formylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate | DHPS, PCBP1, MRPL21 | HRAS 3606/4885ESR1 4748/4885TOP1 601/4885 |
| US-20060067997-A1 | Phospholipid complexes of lexitropsins, their preparation and use in therapeutic formulations | PHOSPHO1, PLTP, NAPEPLD | HRAS 113/4885ESR1 2592/4885TOP1 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.